谢立信主要从事眼科角膜病、白内障的应用基础和临床诊治研究。在角膜病领域，他率先提出并论证了 角膜内皮细胞功能评估的新理论和新标准；组织完成我国首个角膜病流行病学调查，提出多项创新理 论，推动手术变迁；发明我国首个具有独立知识产权的眼内植入环孢素缓释药物；研发角膜活性保存 液、生物角膜、人工角膜等系列产品，缓解了我国角膜供体匮乏问题。在白内障领域，他率先引进超声 乳化白内障联合人工晶体植入微创手术，创新婴幼儿白内障手术方式。他创建山东省眼科研究所，经过 34年发展，现拥有青岛眼科医院、山东省眼科医院（济南）两家三级甲等专科医院，是我国主要眼科中 心之一。 "这个奖，不仅是对我个人成绩的肯定，也是对我团队的认可。我们收获的不只是奖项，更重要的是， 这彰显着中国新时代创造力得到了充分发挥。"谢立信在获奖感言中表示，20年前，他与吴老结识；20 年后，他站在这里，所做的工作得到了认可，这或许是历史的巧合。他83岁了，仍会在医疗、教学、科 研上更加努力，回报社会与这份荣誉。 新京报讯（记者王卡拉）近日在首都医科大学学术报告厅举行的2025年度吴阶平医学奖、吴阶平医药创 新奖颁奖典礼上，中国工程院院士、肿瘤学专家、天津医 ...

12月20日，在优雅的钢琴、小提琴、低音提琴室内乐三重奏和悠扬的歌声中，2025年度吴阶平医学奖、吴阶平医药创新奖颁奖典礼在首都医科大学学术报告 厅拉开帷幕。 第十二届全国政协副主席、中国科学技术协会名誉主席、吴阶平医学奖评审委员会主席、病理生理学家、中国科学院韩启德院士，第十一届全国政协副主 席、生物化学与分子生物学家、中国科学院王志珍院士，中华医学会会长、北京协和医院名誉院长、外科医学家、中国科学院赵玉沛院士及国内医药卫生领 域两院院士、著名专家和首都医科大学师生代表600余人出席了颁奖典礼，共同见证医学界的荣耀时刻。 典礼开始，全体参会人员共同观看吴阶平院士纪念片，影片中讲述了吴阶平院士追求真理、心系患者、献身医学的一生。珍贵的历史画面让在场的每一位观 众深受感动，深刻地理解吴阶平院士"扶伤济世，敬德修业"的医学精神。 张罗校长代表首都医科大学致辞。他指出，吴阶平校长的医学教育理念是一座精神的丰碑，时刻提醒医学的终极价值；也是一束传承的火炬，激励后来者永 葆对生命的敬畏和对科学的热忱。吴阶平医学基金会自成立以来，始终秉承吴老遗志，与首都医科大学血脉相连，携同并进。此次获奖的专家是当代中国医 学界的翘楚和 ...

Core Viewpoint - The article discusses the high-quality development of public hospitals, focusing on the innovative practices and experiences of Shandong First Medical University Affiliated Eye Hospital in the field of ophthalmic medical services [1] Group 1: Talent and Research - The quality of hospital services is primarily dependent on talent and research, with a focus on both attracting and retaining skilled professionals [1] - The hospital invests 10% of its annual revenue in talent development, sending promising doctors for training at top hospitals domestically and internationally to learn advanced medical techniques and concepts [1] - The hospital emphasizes the importance of innovation in research, addressing unresolved issues in ophthalmology, such as developing corneal preservation solutions to extend storage time and improve transplant success rates [1] Group 2: Patient Experience and Service Improvement - The hospital aims to enhance patient access to care, improve treatment outcomes, and reduce costs, with a strong focus on the quality of medical services [1] - Various patient-friendly measures have been implemented, including optimizing the patient experience from outpatient guidance to inpatient treatment, and creating a welcoming environment [1] - The introduction of a day surgery model has reduced patient waiting times and increased operational efficiency, benefiting both patients and the hospital [1] Group 3: Community Engagement and Future Development - The hospital leverages its specialized expertise to enhance the capabilities of grassroots ophthalmic medical services through training, expert support, and telemedicine guidance [1] - The establishment of the Shandong Provincial Ophthalmology Society promotes academic exchange and collaborative development in the field of ophthalmology across the province [1] - Future plans include continuing the dual focus on talent and research while exploring new service models such as smart healthcare and telemedicine to provide more convenient and efficient services to patients [1]

Core Viewpoint - He Eye Hospital's stock price closed at 23.74 yuan on August 12, 2025, reflecting a decrease of 0.54% from the previous trading day [1] Company Overview - He Eye Hospital specializes in ophthalmic medical services, with main business areas including ophthalmic diagnosis and treatment, vision care services, and research and development of ophthalmic medical technologies [1] - The company operates in sectors such as medical services, Liaoning region, and artificial intelligence [1] Market Activity - On August 12, the trading volume was 23,750 hands, with a transaction amount of 0.57 billion yuan [1] - The net outflow of main funds on August 12 was 5.6576 million yuan, with a cumulative net outflow of 14.3488 million yuan over the past five days [1] Strategic Partnerships - As of August 12, the company has not signed any agency or cooperation agreements with Japanese artificial cornea companies [1] - The company is actively monitoring advancements in global ophthalmic technologies and products, including the latest artificial cornea technologies from Japan, the United States, and Europe [1]

Core Viewpoint - Corneal transplantation is a highly successful surgical procedure that replaces damaged corneal tissue with healthy donor corneas, addressing various eye conditions and restoring vision [1][2]. Market Overview - The corneal transplantation market in China is experiencing rapid growth, with the market size projected to reach 824 million yuan in 2024 and 1.286 billion yuan by 2031, reflecting a compound annual growth rate (CAGR) of 6.51% from 2025 to 2031 [4]. - Corneal diseases are a significant cause of blindness, second only to cataracts, making corneal transplantation a critical treatment option in ophthalmic microsurgery [3]. Market Dynamics - The supply of donor corneas is limited and unevenly distributed across regions, particularly affecting rural areas in central and western China [3]. - Recent improvements in eye bank systems, professional training, public awareness, and advancements in artificial cornea technologies are driving market development [3]. Market Segmentation - In 2024, penetrating keratoplasty is expected to dominate the market with a share of 61.41%, followed by lamellar keratoplasty at 21.60% [8]. - The ophthalmology specialty hospitals are the leading institutions for corneal transplantation, with their market size projected to grow from 619 million yuan in 2024 to 952 million yuan by 2031, at a CAGR of 6.33% [9]. Competitive Landscape - Major players in the domestic artificial cornea market include Shenzhen Ainier Cornea Engineering, Mihe Medical, Yueqing Regenerative Medicine, and Jiayue Meishi Biotechnology, with the top four companies holding approximately 87.59% of the market share in 2024 [7]. - The industry is transitioning towards diversified supply, precise treatment, and convenient services, with expectations of maintaining an annual growth rate of over 6% in the coming 5 to 10 years [9]. Supply Chain Analysis - The upstream supply chain primarily consists of voluntarily donated corneas organized by the Red Cross and hospitals, while artificial corneas are produced using high-purity medical-grade polymers and bioactive scaffold materials [11][12]. - Downstream, specialized ophthalmology hospitals and large public hospital eye centers are the main institutions performing the transplants, requiring long-term follow-up care for patients [12].